News headlines about AC Immune (NASDAQ:ACIU) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AC Immune earned a news impact score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 47.1609114941628 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Several research analysts recently issued reports on the company. BidaskClub raised AC Immune from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research raised AC Immune from a “sell” rating to a “hold” rating in a research report on Monday, October 16th.

AC Immune (NASDAQ ACIU) opened at $13.27 on Friday. AC Immune has a 12-month low of $6.03 and a 12-month high of $13.75. The firm has a market capitalization of $728.81 and a PE ratio of -19.81.

WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at

About AC Immune

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Insider Buying and Selling by Quarter for AC Immune (NASDAQ:ACIU)

Receive News & Stock Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related stocks with our FREE daily email newsletter.